Reviewed by Michael Gill, B. Sc.
4 Dalvance Clinical Trials Near Me
Top Cities for Dalvance Clinical Trials
Image of Durham in North Carolina.
Durham
5Active Trials
Duke University Medical Center - Pediatric Infectious DiseasesTop Active Site
Image of Syracuse in New York.
Syracuse
3Active Trials
SUNY Upstate Medical University - Infectious Disease DivisionTop Active Site
Dalvance Clinical Trials by Phase of Trial
Phase 2 Dalvance Clinical Trials
1Active Dalvance Clinical Trials
1Number of Unique Treatments
30Number of Active Locations
Most Recent Dalvance Clinical Trials
Clinical Trial
Began Recruiting Date
Phase

What Are Dalvance Clinical Trials?

Dalvance is a defined treatment for patients suffering from acute bacterial skin and skin structure infections. The infections are caused by susceptible isolates of Staphylococcus aureus, Streptococcus anginosus groups, and Streptococcus pyogenes.

Intravenous administration is the preferred method of ingestion since it comes as a lyophilized powder. The ideal dose for adults is two doses of 1000mg Dalvance and 500mg the following week. For pediatric patients, their age and weight significantly determine their recommended dose.

Why Is Dalvance Studied in Clinical Trials?

Dalvance gets studied in several trials because it helps treat severe skin infections by stopping bacteria growth. Medical practitioners recommend Dalvance treatment for ABSSSI, acute bacterial skin and skin structure infections because of Gram-positive bacteria.

How Does Dalvance Work?

Dalvance works by preventing bacteria growth, treating serious bacterial infections on the skin. It binds to the D-alanyl-D-alanine terminus to interfere with cell wall synthesis, preventing cross-linking. If consumed according to the prescribed amount, it acts as a bactericidal in vitro against Streptococcus pyogenes and Staphylococcus.

How to Use Dalvance

The only way to introduce Dalvance into your system is through a vein injection; a doctor's prescription is crucial. The dose can either be one or two. If two, the second dose should always come a week after the first one.

Your doctor will administer Dalvance through an intravenous infusion (IV), and the process extends to around 30 minutes. It also depends on your response to treatment and medical conditions. To ensure the infection does not return, ensure you complete your subscription even after symptoms disappear.

Using this medication at home requires specific preparation and usage instructions from a licensed health provider. Usually, you should expect a yellow or colorless solution. If you notice any discoloration or particles on the product, avoid using it.

Are There any Side Effects to Using Dalvance?

You should expect headaches, nausea, and diarrhea when taking Dalvance. Although the side effects exist, you should understand the medication's benefit is more remarkable.

If the medicine injection happens too quickly, you may experience the red man syndrome. Tell your doctor immediately to slow down the process.

What Are the Breakthrough Clinical Trials Involving Dalvance?

2014: Acute Bacterial Skin and Skin Structure Infections- This study involved 1312 adults diagnosed with ABSSSI. They prescribed 659 of the patients Dalvance, and the rest a combination of Linezolid and Vancomycin. The patients and doctors did not know each patient's drugs at the beginning of the trial. After 72 hours, the patient evaluation showed the infection had stopped, and the fever had disappeared in Dalvance-prescribed patients.

2019; Invasive Gram-Positive Infections- This study shows Dalvance is an ideal treatment for skin infections caused by invasive gram-positive infections. It involved 45 patients diagnosed with osteomyelitis, uncomplicated bacteremia, and endovascular infection. According to the study, Dalvance demonstrates its role in treating non-ABSSSI invasive gram-positive conditions in specific vulnerable OPAT patients.

Who Are the Key Opinion Leaders on Dalvance Clinical Trials?

Dr. Eurides Lopes, MD

Dr. Eurides Lopes is an infectious diseases specialist with years of experience in hospital medicine. She is currently a director at the Providence Medical Group, with groundbreaking research findings on ABSSSI and other skin infections.

Dr Jacqueline T. Bork

Another critical opinion leader on skin infections and Dalvance is Dr. Jacqueline T. Bork. She is a physician focused on Infectious diseases with interests in antimicrobial stewardship and conditions in immunocompromised patients.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: November 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, Ghazaryan V, Beresnev T, Riccobene T, Patel R, Doernberg SB, Rappo U, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group (ARLG). Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1. https://pubmed.ncbi.nlm.nih.gov/35578360